BioSpace News Archive

Silverback Therapeutics, Inc. today announced that the Company will participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference on Wednesday, October 13, 2021.

Curebase, and the Digital Therapeutics Alliance (DTA), today announced a research and education partnership designed to help digital therapeutics (DTx) organizations conduct effective clinical trials.

Diamond Therapeutics Inc. is pleased to announce the appointment of Dr. Torsten Passie to its scientific advisory board.

Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting

UroGen Pharma Ltd. today announced The Journal of Urology® published results from the Phase 2b OPTIMA II trial, a Phase 2b, open-label, single-arm trial studying UGN-102 (mitomycin) for intravesical solution as primary non-surgical therapy for low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC).

Twist Bioscience Corporation today announced an expansion of its expert-led Alliance Panel product offering.

Better Choice Company today announced that the Company will participate in the LD Micro Main Event and the Dawson James Small Cap Growth Conference in October 2021.

Skye Bioscience, Inc. has appointed Kaitlyn Arsenault, CPA, as Chief Financial Officer.

Tesis Labs, a leader in targeted genetic sequencing, announced $20 million of growth equity financing at a post-money valuation of $520 million.

The Boston Athletic Association (B.A.A.) and Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that Quest will be the exclusive provider of onsite COVID-19 testing for the 125th Boston marathon, to be held Monday, October 11.